Background: Extramedullary relapse is an important cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). This type of relapse is commonly observed in the central nervous system, while it is rare in the testicles and skin. Chimeric antigen receptor-modified T cell (CAR-T) therapy targeting CD19 has shown to be a beneficial treatment approach for relapsed/refractory B cell acute lymphoblasticleukemia (r/r B-ALL). Yet, few studies have reported data regarding the treatment of extramedullary B-ALL relapse, especially both in skin and testicle, with CAR-T therapy.
Case Presentation: Here we reported a single case of a patient with relapsed B-ALL in skin and testicle who was successfully treated by the shRNA-IL6-modified anti-CD19 CAR-T(ssCAR-T-19) therapy. A 29-year-old man with relapsed B-ALL in skin and testicle was enrolled in clinal trial involving the shRNA-IL6-modified anti-CD19 CAR-T(ssCAR-T-19) therapy (ClinicalTrials.gov number, NCT03919240). The patient had toxicity consistent with the grade 1 cytokine release syndrome.
Conclusions: ssCART-19 therapy may be used to effectively eliminate infiltrating leukemia cells in the skin and testicle with mild toxicity, which could be a much safer approach to bridge allo-HSCT, thus further improving the patient's outcome.
Trial Registration: ClinicalTrials.gov number, NCT03919240, Registered 18 April 2019, retrospectively registered.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204010 | PMC |
http://dx.doi.org/10.1186/s40364-020-00193-5 | DOI Listing |
Pol J Vet Sci
September 2024
Ruminant and Swine Clinic, Faculty of Veterinary Medicine, Veterinary University Brno, Palackého třída 1946/1, 612 42 Brno, Czech Republic.
This study focused on continuous monitoring of the immunocontraceptive effect of Improvac® vaccine on the sexual activity of male goats determined by measuring plasma testosterone levels, testicular biometric and ejaculate examination. The animals in the experimental group (n=12) were administered two doses of 2 ml of Improvac® at a four-week interval; the animals in the control group (n=5) received 2 ml of saline. Blood collection, semen collection and testicular measurements were performed at 14-day intervals.
View Article and Find Full Text PDFWorld J Clin Oncol
December 2024
Department of Pathology, Peking University People's Hospital, Beijing 100044, China.
Background: Primary squamous cell carcinoma (SCC) of the middle ear is rare, with non-keratinizing basaloid types being exceptionally uncommon. Distinguishing these cancers, often caused by viral factors (, human papillomavirus or Epstein-Barr virus), or specific genetic alterations (, bromodomain-containing protein 4-nuclear protein in or gene fused with FLI chromosomal rearrangement), from other cranial conditions, is difficult. The recently identified DEK::AFF2 non-keratinizing SCC (NKSCC) is a novel subtype, fitting the World Health Organization classification of head and neck neoplasms.
View Article and Find Full Text PDFAnat Rec (Hoboken)
December 2024
Department of Comparative Anatomy, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University, Krakow, Poland.
Chameleons are a family of lizards distinguished by several unique features related to their arboreal lifestyles, such as a ballistic tongue, skin color changes, independent movement of both eyes, a prehensile tail, and cleft hands and feet. The veiled chameleon (Chamaeleo calyptratus) has been proposed as a promising model species for studying squamate biology. Despite its potential, the developmental biology of this species remains poorly understood, particularly in terms of gonadal development.
View Article and Find Full Text PDFBackground: Junctional hemorrhage is a leading cause of battlefield death. Multiple FDA-approved junctional tourniquet (JTQ) models demonstrate effective hemorrhage control in laboratory settings. However, there are few real-world use cases within the literature.
View Article and Find Full Text PDFJ Invest Dermatol
November 2024
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; Cancer Biology Research Program, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA. Electronic address:
Melanoma is an aggressive skin cancer with a high tendency for metastasis and resistance to conventional therapies. This study explores the role of preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, in melanoma progression, focusing on its function in melanoma-derived extracellular vesicles (EVs) and its impact on benign melanocytes. We show that PRAME is highly expressed in melanoma cell lines, tissues, and patient plasma and is present in EVs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!